Sage Journals: Discover world-class research

Retricted access

Research article

First published 2006-03

Acetazolamide 125 mg BD Is Not Significantly Different from 375 mg BD in the Prevention of Acute Mountain Sickness: The Prophylactic Acetazolamide Dosage Comparison for Efficacy (PACE) Trial

Buddha Basnyat, Jeffrey H. Gertsch, Peter S. Holck [...]

High Altitude Medicine & Biology

Free access

Research article

First published 2019-03

Reduced Acetazolamide Dosing in Countering Altitude Illness: A Comparison of 62.5 vs 125 mg (the RADICAL Trial)

Scott E. McIntosh, Mika Hemphill, Marion C. McDevitt [...]

Wilderness & Environmental Medicine

Free access

Abstract

First published 2017-12

Reduced Acetazolamide Dosing for Acute Mountain Sickness Prevention Study: A Comparison of 62.5 vs 125 mg BID (the RAD AMS prevention study)

Scott McIntosh, Mika Hemphill, Marion McDevitt [...]

Wilderness & Environmental Medicine

Retricted access

Research article

First published 2004-03

A Dose–Response Study of Acetazolamide for Acute Mountain Sickness Prophylaxis in Vacationing Tourists at 12,000 Feet (3630 m)

Chris Carlsten, Erik R. Swenson, Stephen Ruoss

High Altitude Medicine & Biology

Retricted access

Other

First published 2001-08

Acetazolamide Treatment for Infantile Central Sleep Apnea

Heike Philippi, Imke Bieber, Bernd Reitter

Journal of Child Neurology

Free access

Research article

First published 2011-3

Spironolactone Does Not Prevent Acute Mountain Sickness: A Prospective,Double-Blind,Randomized,Placebo-Controlled Trial by SPACE Trial Group (Spironolactone and Acetazolamide Trial in the Prevention of Acute Mountain Sickness Group)

Buddha Basnyat, Peter S. Holck, Matiram Pun [...]

Wilderness & Environmental Medicine

Free access

Research article

First published 2007-12

Ginkgo biloba Decreases Acute Mountain Sickness in People Ascending to High Altitude at Ollagüe (3696 m) in Northern Chile

Fernando A. Moraga, Alejandro Flores, Jordi Serra [...]

Wilderness & Environmental Medicine

Search results

Acetazolamide 125 mg BD Is Not Significantly Different from 375 mg BD in the Prevention of Acute Mountain Sickness: The Prophylactic Acetazolamide Dosage Comparison for Efficacy (PACE) Trial

Reduced Acetazolamide Dosing in Countering Altitude Illness: A Comparison of 62.5 vs 125 mg (the RADICAL Trial)

Reduced Acetazolamide Dosing for Acute Mountain Sickness Prevention Study: A Comparison of 62.5 vs 125 mg BID (the RAD AMS prevention study)

A Dose–Response Study of Acetazolamide for Acute Mountain Sickness Prophylaxis in Vacationing Tourists at 12,000 Feet (3630 m)

Acetazolamide Treatment for Infantile Central Sleep Apnea

Spironolactone Does Not Prevent Acute Mountain Sickness: A Prospective,Double-Blind,Randomized,Placebo-Controlled Trial by SPACE Trial Group (Spironolactone and Acetazolamide Trial in the Prevention of Acute Mountain Sickness Group)

Ginkgo biloba Decreases Acute Mountain Sickness in People Ascending to High Altitude at Ollagüe (3696 m) in Northern Chile